Business
Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress
Company-sponsored webinar to be announced CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome
About this update from Editas Medicine, Inc.
[{"type":"text","content":"Company-sponsored webinar to be announced\nCAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that a scientific abstract detailing safety and efficacy clinical data from the Phase 1/2 RUBY trial of EDIT-301 in patients with severe sickle cell disease has been accepted for an oral presentation at the European Hematology Association (EHA) Hybrid Congress being held June 8-11, 2023, in Frankfurt, Germany, and via live stream. Key data from multiple patients will be shared in the oral presentation at EHA, confirming initial clinical data, include: Efficacy data, including total hemoglobin, fetal hemoglobin, percentage of F-cells, mean corpuscular fetal hemoglobin, and vaso-occlusive events (VOEs) post-infusion with EDIT-301.Safety data, including neutrophil and platelet engraftment. “We are making significant progress with EDIT-301, and we look forward to sharing clinical data, including additional data that has been collected since the submission of the abstract, from the RUBY trial next month at the European Hematology Association Congress and in a Company-sponsored webinar. This data further supports our belief that EDIT-301 can be a potentially clinically differentiated, one-time, durable medicine that can provide life-changing clinical benefits to patients,” Baisong Mei, M.D., Ph.D., Senior Vice President and Chief Medical Officer, Editas Medicine. “I would like to thank the participants, their families, clinicians, and colleagues at collaborating institutions that contribute to the RUBY trial.” The abstract can be accessed on the EHA website. Oral Presentation Details: Title: EDIT-301 Shows Promising Preliminary Safety and Efficacy Results in the Phase I/II Clinical Trial (RUBY) of Patients with Severe Sickle Cell Disease Using Highly Specific and Efficient AsCas12a EnzymePresenting Author: Rabi Hanna, M.D., Department of Pediatric Hematology Oncology and Blood and Marrow Transplantation, Cleveland Clinic Children’s, Cleveland, OH, United StatesDate/Time: Saturday, June 10, 2023, 4:30 – 5:45 p.m. CEST/ 10:30 – 11:45 a.m. EDTLocation: Harmonie 1, Messe FrankfurtSession: s437 Gene therapy and cellular immunotherapy – Clinical EDIT-301 is currently being investigated in a clinical study in patients with severe sickle cell disease (RUBY ...